Herpes zoster after autologous haematopoietic stem cell transplantation without antiviral prophylaxis

Shinohara, Akihito; Osanai, Satoko; Izuka, Yuki; Ryuzaki, Michiko; Watanabe, Aya; Tanaka, Norina; Ishiyama, Midori; Kojima, Hiroshi; Hagiwara, Shotaro; Yoshinaga, Kentaro; Sekiguchi, Masayuki; Tanaka, Junji

doi:10.1111/bjh.16072

Cited by 1 publication

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 A known complication is the development of herpes zoster (HZ) after ASCT. [2][3][4][5][6][7][8] A prophylaxis with acyclovir is described as effective in some studies. [9][10][11][12][13][14][15] It is currently an open question, which acyclovir dose is beneficial.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Herpes zoster prophylaxis with low‐dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation

Abbasov

Metzner

Müller

et al. 2022

European J of Haematology

View full text Add to dashboard Cite

Background Herpes zoster (HZ) is a frequent complication after autologous stem cell transplantation (ASCT). The option of zoster prophylaxis with an antiviral drug is described in the literature, but there is no consensus on the drug and the dosage. Patients and Methods We analyzed the records of 310 patients treated with ASCT who were controlled regularly regarding HZ inter alia for at least 24 months following ASCT. Since 01/2015 patients received prophylactic low‐dose acyclovir (400 mg per day) during the first 12 months following discharge after ASCT (n = 107). Results Twenty percent of patients without this kind of prophylaxis and 2.8% of patients with prophylaxis developed HZ (p < .001). No patient with this prophylaxis developed HZ in the first year after ASCT, 2.8% of patients in the second year after ASCT. A prognostic factor was the kind of diagnosis: 30% of lymphoma patients and 14% of myeloma patients developed HZ in the first 24 months after ASCT without prophylaxis, but only 6.3% and 0% of patients with prophylaxis, respectively. Neither an increase of HZ cases following prophylaxis nor acyclovir refractory HZ cases were observed. Conclusions Zoster prophylaxis with low‐dose acyclovir over 12 months after ASCT is effective and well tolerated.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Therefore, the number of ASCT rises continuously in Europe and collaborating countries 1 . A known complication is the development of herpes zoster (HZ) after ASCT 2–8 . A prophylaxis with acyclovir is described as effective in some studies 9–15 .…”

Section: Introductionmentioning

confidence: 99%